GB2355191A — Combination formulations for fatigue, head injury and strokes
Assigned to Laxdale Ltd · Expires 2001-04-18 · 25y expired
What this patent protects
Formulations for the treatment of fatigue, in particular chronic fatigue and fibromyalgia, combine a selective inhibitor of noradrenaline uptake with either phenylalanine or tyrosine in the same dosage forms or the same packs. The noradrenergic drug may be lofepramine, desipramin…
USPTO Abstract
Formulations for the treatment of fatigue, in particular chronic fatigue and fibromyalgia, combine a selective inhibitor of noradrenaline uptake with either phenylalanine or tyrosine in the same dosage forms or the same packs. The noradrenergic drug may be lofepramine, desipramine or reboxetine. The drug may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion. Unit dosages contain 100-1000mg of phenylalanine or tyrosine together with 50-100mg of lofepramine or desipramine or 2-5mg of reboxetine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.